Mankind Pharma , a prominent player in the Indian pharmaceutical sector, has announced its financial results for the quarter and half year ended September 30, 2025, showcasing significant revenue growth.

Key Financial Highlights

Revenue Growth and Profit Increase

Mankind Pharma demonstrated strong financial performance in the second quarter of FY2026. The company reported revenue from operations of ₹2,608.78 crores, representing a 15.4% increase from ₹2,261.43 crores in the same quarter of the previous year. This substantial rise in revenue indicates robust demand for the company's pharmaceutical products.

The company's bottom line also showed significant improvement. The net profit for Q2 FY2026 stood at ₹458.90 crores, marking a 26.5% increase from the ₹362.68 crores reported in the same quarter of the previous year.

Half-Year Performance

For the six-month period ended September 30, 2025, Mankind Pharma's revenue reached ₹4,956.80 crores, compared to ₹4,497.80 crores in the corresponding period of the previous year, indicating continued growth momentum.

Earnings Per Share

The company's earnings per share (EPS) for the quarter improved to ₹11.10, up from ₹10.00 in the prior year quarter, reflecting an 11% increase.

Corporate Governance

The Board of Directors approved these unaudited standalone and consolidated financial results at their meeting held on November 6, 2025, demonstrating the company's commitment to timely financial reporting and transparency.

Ongoing Legal Proceedings

Mankind Pharma continues to face ongoing income tax proceedings initiated by the Income Tax Department under Section 132 of the Income Tax Act, 1961. The company has noted that appeals are currently pending with appellate tax authorities.

The strong financial performance, particularly in revenue growth and profitability, positions Mankind Pharma favorably in the pharmaceutical market. However, the ongoing tax proceedings may require careful management attention in the coming periods.

Mankind Pharma , a prominent player in the Indian pharmaceutical industry, has recently received an Environmental, Social, and Governance (ESG) rating from MSCI ESG Ratings and Research Private Limited. This development marks a significant step in the company's commitment to sustainable and responsible business practices.

ESG Rating Details

Disclosure and Transparency

Mankind Pharma has taken steps to ensure transparency regarding this ESG assessment:

1. The company has made the ESG report available on its official website ( www.mankindpharma.com ).
2. In compliance with SEBI regulations, Mankind Pharma has informed both the BSE Limited and the National Stock Exchange of India Limited about this development.

Regulatory Compliance

The disclosure of the ESG rating aligns with Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This move demonstrates Mankind Pharma's commitment to meeting regulatory standards and maintaining open communication with stakeholders.

Implications of the ESG Rating

While the specific implications of the 'B' rating are not detailed in the provided information, ESG ratings generally offer insights into a company's performance across environmental, social, and governance factors. These ratings may influence investor perceptions and decisions, particularly for those focused on sustainable and responsible investing.

As the pharmaceutical industry faces increasing scrutiny on issues ranging from environmental impact to social responsibility, Mankind Pharma's engagement with ESG ratings indicates its awareness of these evolving market expectations.

Investors and stakeholders may view this rating as a benchmark for Mankind Pharma's current ESG performance and may look for future improvements or initiatives in these areas.